Core Viewpoint - Morgan Stanley has raised the target price for MicroPort Scientific Corporation (02252) from HKD 30.9 to HKD 42, maintaining an "Overweight" rating and identifying the stock as a top choice in China's medical technology sector, indicating that the recent price pullback presents a good buying opportunity [1] Group 1: Company Performance - MicroPort's global order momentum remains strong, with over 170 surgical robot orders accumulated as of last Wednesday, up from 150 orders at the end of August [1] - The installation of the Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with applications in nearly 40 countries and major hospital systems, driving strong adoption [1] Group 2: Financial Projections - Based on approximately 100 cumulative orders for Toumai, the company has revised its installation forecast for this year from 84 units to 105 units, primarily due to overseas growth and the assumption that orders can be converted to sales within less than a quarter [1] - An improved installation base and product mix, along with an expected gross margin improvement of 1 to 1.5 percentage points, are anticipated [1]